Avatrombopag Receives FDA Approval for Treamtent of Pediatric Patients With Chronic Immune Thrompcytopenia
Pharmacy Times
JULY 25, 2025
Common adverse reactions in pediatric patients included viral infections, nasopharyngitis, and cough, but the drug was generally well-tolerated. The AVA-PED-301 study showed significant efficacy of avatrombopag in achieving durable platelet response in children.
Let's personalize your content